Compare AbCellera Biologics Inc (ABCL) vs Palo Alto Networks Inc (PANW) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Palo Alto Networks (PANW) trades at $337.04, down 3.17% today but remains near all-time highs with strong bullish momentum. The stock has surged over 150% from yearly lows, driven by robust cybersecurity demand and AI-driven security solutions. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.85 surpassing the $0.793 estimate. Revenue growth remains solid at $9.22B for 2025, though valuation multiples appear elevated with a P/E of 310.9 and P/S of 24.82. Technical indicators show mixed signals with moving averages bullish but RSI levels suggesting overbought conditions.

Outlook: PANW benefits from durable growth drivers including platformization and AI cybersecurity adoption, with analysts projecting a 19-23% upside to consensus targets. Risks include premium valuation sensitivity, integration costs from acquisitions, and competitive pressures. The stock's trajectory hinges on execution of its $20B NGS ARR target by 2030 and maintaining industry leadership amid rising AI threats. Near-term support lies at $324, with resistance at $371.